Plasmacytoid dendritic cells (pDCs) are important mediators of the early innate immune 60 response to viral infection through robust production of type I interferons (IFNs), particularly 61
IFNα (1, 2) . pDCs recognize single-stranded RNA and unmethylated CpG-rich DNA through 62 activation of toll-like receptor (TLR)7 or TLR9 (3-5), respectively, which results in activation of 63 NF-κB and interferon regulatory factory 7 (IRF7) to induce cytokine production. The 64 constitutive expression of high levels of IRF7 by pDCs allows for rapid production of type I 65 IFNs (6). Type I IFNs contribute to the immune response through inhibition of viral replication 66 (7), as well as by mediating activation and survival of myeloid dendritic cells (mDCs), 67 macrophages, natural killer cells, and T cells (8). Loss of pDC function early after infection 68 could thus have critical effects on the propagation of the immune response. To date, little is 69 known about the pDC response during the earliest stages of HIV-1 infection, prior to detection of 70 viral RNA, or how this response contributes to subsequent immune control or disease 71 progression. 72 73 HIV-1 infection induces a marked alteration of pDC frequency and function after peak viremia 74 that correlates with disease progression. Frequencies of pDCs are lower in the blood of people 75 living with HIV-1 than in uninfected individuals and are only partially restored after 76 antiretroviral therapy (ART)(9-14). In viremic individuals, pDC frequency positively correlates 77 with CD4 count and inversely correlates with plasma viral load (VL) (15). pDCs from 78 individuals with HIV-1 have a reduced capacity to produce IFNα following in vitro stimulation 79 with TLR7 or TLR9 ligands, HIV-1, and other viruses (14, 16-18). HIV-1 infection affects IFNα 80 production by altering both the intracellular signaling capability of pDCs and the phenotypic 81 make-up of the pDC population in the blood. Exposure of pDCs from healthy donors to HIV-1 in 82 vitro results in a delay and reduction of IFNα production compared to TLR7 agonists and other 83 viruses (19, 20) . This delay has been associated with increased phosphorylation of spleen 84 tyrosine kinase (SYK) due to engagement of gp-120 with the pDC marker CD303 (19) and 85 decreased nuclear translocation of IRF7 due to decreased phosphorylation of Akt (21) . 86 Furthermore, decreased production of IFNα has been associated with an increase of Tim-3 + 87 exhausted pDCs present in the blood during HIV-1 infection (22), increased CD40 expression on 88 blood pDCs during HIV-1 infection (23), and the mobilization of immature pDCs from the bone 89 marrow after SIV infection (24-26). These studies were mostly performed with pDCs from 90 healthy donors exposed to HIV-1 in vitro, or with pDCs obtained from individuals during the 91 chronic stage of HIV-1 infection. 92 93 Limited knowledge about the function of pDCs during the earliest stages of infection, prior to 94 detection of plasma viral RNA, has been derived from non-human primate models. pDCs are the 95 first major cell population recruited to the vaginal mucosa after SIV infection in rhesus 96 macaques, where they accumulate beneath the endocervical epithelium and produce IFNα within 97 one day of infection (27) . A transient increase in the frequency of pDCs in the blood has also 98 been reported to occur prior to peak viremia after intravenous SIV infection (25, 26, 28) . 99
Frequent sampling of plasma after intravenous SIV inoculation of African green monkeys 100 (AGMs) revealed a low, transient increase in plasma IFNα levels two days post infection, prior 101 to a subsequent robust increase in plasma IFNα levels that accompanies viremia (29). It is 102 logistically difficult to determine if a similar increase in plasma IFNα levels occurs within days 103 of HIV-1 infection, however plasma IFNα levels are one of the first to increase during the initial 104 cytokine storm that occurs after HIV-1 infection, similar to what has been described in SIV 105 infection (28, 30) . The importance of the early IFNα response has been shown by decreased SIV 106 acquisition when rhesus macaques were treated with Type-I IFNs (31, 32) and more rapid 107 disease progression when treated with an IFN-I receptor antagonist (31). However, the 108 uncontrolled type I IFN response after acute HIV and pathogenic SIV infection is associated with 109 chronic immune activation and disease progression even in treated individuals (29, (33) (34) (35) (36) . 110
111
Although it is challenging to measure the early pDC response during the eclipse phase of acute 112
HIV-1 infection (AHI), when virus is not yet detectable in the blood, it is possible to monitor the 113 immune response to the initial low-level viral replication in the tissues after the ART interruption 114 in aviremic individuals. The identification of post-treatment controllers, who maintain 115 undetectable viral loads for years after treatment cessation (37), has led to an increased interest in 116 identifying therapeutic interventions to induce control after analytic treatment interruption (ATI). 117 ATI also allows measurement of the early innate immune response to HIV replication. Three 118 ATI studies have been completed with participants in the RV254 cohort, a unique group of 119 individuals living with HIV-1 in Thailand who initiated ART during AHI (Fiebig stages I-V) 120 (38, 39): the single arm RV411 study of ATI after very early ART initiation during Fiebig I (40), 121 the RV409 study of vorinostat, hydroxychloroquine, and maraviroc (VHM) with ART vs. ART 122 alone (control arm) followed by ATI (Kroon, unpublished observations), and the RV397 study of 123 VRC01 broadly neutralizing antibody vs. placebo administration during ATI (41). Here, we 124 analyzed the mobilization, activation, and function of pDCs in the blood of participants in these 125 three ATI studies to identify markers of viral replication prior to detection of viremia by standard 126 commercial assays (³20 copies/mL). Although these data are from three different clinical trials 127 with limited numbers of participants, these participants are homogenous in age, virus clade, and 128 time of ART initiation. 129
Results 130
pDCs are mobilized into the blood prior to detection of viremia after ATI 131
To study the innate response prior to detectable viremia, we analyzed longitudinal samples from 132 participants enrolled in three separate ATI studies: RV411, RV409, and RV397 (Table 1 , 133
Supplemental Figure 1 ). Activation of innate cells, including pDCs, was measured prior to ATI 134 in the participants of RV409 who received VHM, so only participants in the control arm of 135 RV409, who received no therapeutic intervention, were included in the current analysis. All 136 participants in all three trials experienced viral rebound during ATI. 137
138
We examined the presence of pDCs in the blood after ATI to look for indications of pDC 139 mobilization prior to detection of viremia. There was a transient increase in the frequency of 140 pDCs (Lin -HLA-DR + CD11c -CD303 + , Figure 1A ) in the blood prior to the detection of plasma 141 viral RNA ( Figure 1B ). In participants for which the absolute pDC count could be calculated, we 142 found that the transient increase in pDC frequency approximated a similar increase in absolute 143 pDC count (Supplemental Figure 2A ). As pre-rebound samples from RV411 participants were 144 limited to the baseline visit, when treatment was interrupted, and the last visit at which the 145 participant was aviremic (VL<20 copies/mL), we used these time points to quantify changes in 146 pDC frequency prior to detection of viremia in the three ATI cohorts. A significant increase in 147 pDC frequency occurred between the baseline ATI visit and the last aviremic visit (median 7.6% 148 vs median 10.8%, p<0.001)( Figure 1C ). As administration of VRC01 antibody to participants in 149 RV397 could have altered their pDC response, we confirmed that there was a significant increase 150 of pDC frequency in the blood of the participants who underwent ATI in the absence of 151 therapeutic treatment (p<0.001)(Supplemental Figure 2B ) and that there was no significant 152 difference in the fold change of pDC frequency between the placebo and treatment arms of 153 RV397 (Supplemental Figure 2C ). In contrast, ART-only treated participants in RV409 showed 154 no increase in pDC frequency during the 10 weeks prior to ATI ( Figure 1D ), suggesting the 155 transient increase seen after ATI is an early response to viral replication that follows ART 156 interruption. Importantly, this increase was specific to pDCs, as a similar increase was not found 157 within the frequency of CD1c + mDC, CD141 + mDC, CD14 + CD16classical monocyte, 158 This maturation is characterized by increased expression of the costimulatory marker CD86 and 173 the maturation marker CD83, among others (42, 43, 45). There was no difference in the 174 expression levels of CD86 or CD83 on pDCs prior to detectable viremia after ATI ( Figure 2C) . 175
There were also no significant differences in expression of activation markers between arms in 176 RV397 (Supplemental Figure 4) . These data indicate that after ATI, pDCs entering the blood 177 prior to detection of viremia are activated but not differentiated. 178 179 pDCs are primed to traffic to sites of inflammation prior to detection of viremia 180
To assess the destination of the pDCs entering the blood, we analyzed the expression of pDC 181 surface proteins involved in cell trafficking. Due to sample availability, all remaining 182 experiments were performed on samples from RV397 only. pDCs showed no changes in 183 expression of the chemokine receptors CCR7 or CCR9 prior to detectable viremia, but did have 184 decreased expression of integrin β7, which mediates homing to mucosal sites (46), at the last 185 aviremic time point compared to baseline ATI (392 vs 299, p<0.05; Figure 3A ). pDCs had 186 increased expression of CD29 (integrin β1)(1905 vs 2535, p<0.05), which is used for firm 187 adhesion prior to extravasation from the blood vessel (47), and CXCR4 (1010 vs 1516, p<0.01), 188 which mediates chemotaxis to lymph nodes via high endothelial venules, particularly during 189 inflammation ( Figure 3A ). No differences were observed between placebo and treatment arms 190 for all of the measured markers. Further, plasma levels of stromal cell-derived factor 1α (SDF-191 1α), the primary ligand for CXCR4, were also elevated relative to baseline ATI prior to 192 detectable viremia (126 vs 255, p<0.01)( Figure 3B ). These data suggest that the pDCs are 193 primed for recruitment to secondary lymph organs and extravasation at sites of inflammation. 194
195

Transient loss of interferon production occurs in pDCs prior to detection of viremia 196
As these changes to pDCs occurred prior to detection of viral RNA in the blood, we assessed 197 their functional capacity to respond to virus by measuring IFNα and TNFα production after 198 stimulation with the TLR7 agonist imiquimod ( Figure 4A ). Prior to detectable viremia, there was 199 a transient decline in the percentage of pDCs which produced IFNα upon in vitro stimulation 200 ( Figure 4B ). As this drop in IFNα production tended to correspond with peak pDC frequency, we 201 compared the frequency of cells producing IFNα at the time of peak pDC frequency with that of 202 the week prior to peak pDC frequency. There was a significant decline in the frequency of IFNα + 203 pDCs (19.6% vs 14.1%, p<0.05)( Figure 4C ) and a trend towards a lower frequency of TNFα + 204 pDCs (54.2% vs 45.3%, p=0.08)( Figure 4D , Supplemental Figure 5A ) at the time of peak pDC 205 frequency. It is important to note that the four participants with increased frequencies of IFNα + 206 pDCs at the time of peak pDC frequency had the lowest frequencies of IFNα + pDCs at the visit 207 prior. For two of these participants, the decreased capacity of pDCs to produce IFNα after 208 stimulation occurred the week prior to peak pDC frequency, when the frequencies of pDCs in the 209 blood had increased but not yet reached maximum. For the other two participants, rebound 210 occurred very early, within just 2 weeks of treatment interruption, and the limited sampling prior 211 to rebound may not have been sufficient to capture the transient decline. Moreover, there was a 212 trend towards decreased IFNα MFI at the time of peak pDC frequency among all participants 213 (7144 vs 6442, p=0.15)(Supplemental Figure 5B ), suggesting that not only were fewer cells able 214 to produce IFNα, but also that less IFNα could be produced on a per cell basis after in vitro 215 stimulation. 216 217 pDC activation in participants with extended aviremia 218
The two participants in RV397 with the longest time off ART before detection of viremia (³ 20 219 copies/mL) both had an increased frequency of pDCs in the blood after ATI, with transient 220 increases in expression of activation markers ( Figure 5A ). Participant 7242 had a delayed 221 rebound of 65 days, but showed an increased frequency of pDCs in the blood with a decreased 222 capacity to produce IFNα one week after ATI. pDC function in Participant 7242 recovered three 223 weeks after ATI but was lost again prior to detection of viremia. While Participant 3499 224 experienced the longest time to rebound (42 weeks), there was a viral blip identified by a high 225 sensitivity single-copy assay and an increased frequency of pDCs in the blood was observed 226 immediately before this viral blip. A transient impaired capacity to produce IFNα after in vitro 227 stimulation was also seen in these two participants ( Figure 5B ). Despite a viral blip of less than 2 228 copies/mL six weeks after ATI, pDCs from Participant 3499 still showed decreased capacity to 229 produce IFNα prior to the blip. Participant 7242 did not have a detectable viral blip by single-230 copy assay, but six of the other participants in RV397 had measurable virus of 2.1 copies/mL or 231 less at the last time point the participant was considered aviremic (VL<20 copies/mL). One of 232 these participants had a viral load of just 21 copies/mL at the first visit viral load was detectable 233 by commercial assay, but already had a viral load of 1.5 copies/mL one week prior as measured 234 by the single copy assay. These data indicate that viral replication may begin over a week before 235 it is detectable by commercial assays, and suggest that the increased frequency and decreased 236 function of pDCs after ATI may be a marker for low level viral replication, even when detectable 237 viremia does not occur until weeks or months later. 238
pDCs undergo a refractory state prior to detection of viremia 240
Previous studies reported a decline in IFNα production by pDCs after peak viremia during acute 241 SIV and HIV-1 infections or after detectable viremia during treatment interruption (14, 16-18, 242 22, 23, 48). In SIV infection, this decline was attributed to an egress of immature pDCs from the 243 bone marrow into the blood after peak viremia (25). To determine whether the increased 244 frequency of pDCs in the blood prior to detection of viremia was due to bone marrow egress, we 245 measured the frequency of cells expressing Ki-67, a marker of immature pDCs (26). There was 246 no difference in the frequency of Ki-67 + pDCs between the week of peak pDC frequency 247 compared to the week prior (Supplemental Figure 6A ), suggesting that the decreased frequency 248 of IFNα + pDCs after in vitro stimulation was not due to an influx of immature cells in blood. An 249 inability to produce IFNα has also been attributed to exhaustion of pDCs over time during HIV-1 250 infection (22). To determine if the decreased ability to produce IFNα at the time of peak pDC 251 frequency was due to an influx of exhausted cells, characterized by Tim-3 expression, we 252 measured the frequency of Tim-3 + pDCs. At the time of peak pDC frequency, there was a 253 decline in the frequency of pDCs expressing Tim-3 compared to the week prior (7.3% vs 5.7%, 254 p<0.01)(Supplemental Figure 6B ). Thus, the decreased IFNα production seen prior to detectable 255 viremia was not a result of an influx of exhausted pDCs into the blood. 256 257 During in vitro activation of pDCs with HIV-1, there is a delayed production of IFNα that has 258 been associated with increased phosphorylation of the signaling molecule SYK as a result of 259 interactions between gp-120 and CD303 (19). To assess if the decreased IFNα production by 260 pDCs was due to exposure to gp-120 in vivo, we measured the basal percentage of SYK 261 phosphorylation in eight RV397 participants at a visit prior to ATI (pre-ATI visit) and a visit 262 with the nadir IFNα response or the only available visit remaining after ATI (ATI visit). There 263 was a significant increase in the percentage of SYK phosphorylation at the ATI visit compared to 264 the pre-ATI visit (median 68.1% vs 58.7%, p<0.01)(Supplemental Figure 7A ). However, there 265 was no correlation between the basal levels of SYK phosphorylation and the capacity to produce 266 IFNα. Thus, while these data suggest that a portion of the pDCs may have come in contact with 267 HIV-1 in vivo resulting in higher SYK phosphorylation, this phosphorylation did not appear to 268 be the cause of the decreased IFNα production in vitro. 269
270
The decreased IFNα production in vitro could also be a result of the pDCs being in a refractory 271 state after in vivo activation by HIV-1 (18, 49). We measured the capability of pDCs from eight 272 participants in RV397 to phosphorylate IRF7 (pIRF7) and NF-κB (pNF-κB), key transcription 273 factors in the production of IFNα and TNFα, respectively. We assessed whether the capacity to 274 activate IRF7 or NF-κB correlated with IFNα production. There were negative correlations 275 between the levels of pIRF7 or pNF-κB after stimulation and the loss of IFNα capacity, as 276 measured by the fold decrease in IFNα + pDCs after in vitro stimulation at the ATI visit compared 277 to the week prior (r = -0.76, p<0.05, r = 0.71, p=0.06, respectively)( Figure 6A was hampered. We further hypothesized that if the pDCs were in a refractory state due to 281 activation by HIV-1, then earlier production of IFNα in vivo would be seen by higher plasma 282 IFNα2 levels. Along these lines, we found that there was a negative correlation between plasma 283
IFNα2 levels at the ATI visit and the levels of pIRF7 (r = -0.78, p<0.05) and pNF-κB (r = -0.64, 284 p=0.10) in pDCs after imiquimod stimulation ( Figure 6B , Supplemental Figure 7D ). In contrast, 285 the levels of pIRF7 and pNF-κB after imiquimod stimulation of a sample from before ATI 286 correlated with the plasma IFNα2 levels at the ATI visit (r=0.79, p<0.05, r=0.92, p<0.01, 287 respectively)( Figure 6C , Supplemental Figure 7E ), indicating that the pDCs had the capacity to 288 phosphorylate IRF7 before ATI. Cumulatively, these data suggest that prior to detectable viremia 289 after ATI pDCs are activated and produce IFNα before entering into a refractory state. 290 291 It has been reported that IRF7 mRNA levels are lower in pDCs from people living with HIV-1 292 during both chronic untreated infection and after ART, resulting in lower IFNα production (50, 293 51). To determine if the decreased IFNα production measured after ATI was related to decreased 294 expression of key signaling molecules, we measured the mRNA levels of interferons, multiple 295 cytokines and chemokines, surface receptors, and signaling genes in sorted pDCs from pre-ATI 296 and ATI samples from eight separate RV397 participants ( Figure 7A ). Several genes showed 297 lower expression in pDCs from the ATI visit compared to the pre-ATI visit. In particular, genes 298 related to type I IFN signaling were lower at the ATI visit, including: IRF7 (median 1.44-fold, 299 p<0.05) ; TLR7 (median 1.29-fold, p<0.01); STAT1 (median 1.57-fold, p<0.01); and two 300 interferon-stimulated genes (MX1, median 1.77-fold, p<0.01; MX2, median 1.41-fold, p<0.01), 301 with the latter four genes maintaining significance after correction for multiple comparisons 302 ( Figure 7A ). To determine if the changes in interferon signaling genes were intrinsic to pDCs or 303 were common to other innate cells, we also measured gene expression in sorted CD1c + mDCs 304 (Supplemental Figure 7F ). mDCs had very little change in gene expression between the pre-ATI 305 and ATI time points, only showing a decrease in MX2 expression (1.34-fold, p<0.05) and an 306 increase in IRF1 expression (1.40-fold, p<0.01) neither of which remain significant when 307 corrected for multiple comparisons. These data suggest that there is a pDC-specific loss in 308 expression of genes related to type I IFN signaling that may contribute to the loss of in vitro 309 IFNα production. 310 311 Consistent with the decreased in vitro IFNα production, pDCs had lower expression of type I 312 IFN genes. IFNA5 and IFNB1 transcript levels were 2.14-and 1.87-fold lower in the pDCs from 313 the ATI visit, respectively (p<0.05)( Figure 7A ). Though the 2.53-fold decrease in IFNA2 314 expression did not remain significant after correcting for multiple comparisons, there was a 315 significant positive correlation between the expression levels of IFNA2 at the ATI visit and the 316 subsequent plasma IFNα2 levels measured after rebound (r=0.9048, p<0.01)( Figure 7B ). A 317 similar correlation between IFNA2 expression and rebound plasma IFNα2 levels was not found 318 in the mDCs (Supplemental Figure 7G ), suggesting that pDC function after ATI drives early 319
IFNα production after rebound. Interestingly, there were negative correlations between the levels 320 of expression of type I IFN genes and the time from the ATI visit to viral detection (VL³20 321 copies/mL)( Figure 7C ). IFNA1, IFNA2, IFNA7, and IFNA8 levels were all significantly 322 negatively correlated with time to viral detection after correction for multiple comparisons (r=-323 0.9132, p<0.01 for all), and IFNA21/1 and IFNB1 levels only reached significance without 324 correction (r=-0.8498 and -0.7864, respectively, p<0.05). These data suggest that the loss of type 325 to distal sites, we hypothesized that mobilization of innate immune cells should be evident in the 345 blood. Our data demonstrate the presence of an increased frequency of activated pDCs in the 346 blood prior to detectable viremia after ATI (Step 4). Peripheral blood pDCs were activated, as 347 measured by expression of CD69, PD-L1, and CD40, but had not differentiated into antigen-348 presenting cells expressing CD83 and CD86. These cells also expressed increased CXCR4 and 349 CD29, suggesting they are being trafficked to sites of inflammation (56, 57). Consistent with the 350 immature phenotype of the pDCs there was no increase of CCR7 expression prior to detectable 351 viremia, and the pDCs will be responsive to the higher levels of SDF-1α in the plasma at this 352 time (58). A partially activated phenotype, similar to that seen here, has previously been 353 associated with an ability to continuously produce IFNα by pDCs exposed to HIV-1 in vitro (44). 354 However, pDCs in the blood of ATI participants showed a transient decline in the ability to 355 produce IFNα after in vitro stimulation (Step 5), similar to the refractory state that has been 356 reported in pDCs from after peak viremia during AHI, after rebound in ATI, and in SIV-infected 357
AGMs (14, 16-18, 59). 358
359
Identification of a refractory state instead of a state of persistent IFNα production may depend on 360 the timing of HIV-1 exposure and IFNα measurement. pDCs are refractory to IFNα production 361 after multiple in vitro stimulations with influenza virus, R848, or CpGB, indicating a mechanism 362 to control persistent activation and IFNα production (44, 60). However, IFNα production is 363 delayed in pDCs stimulated with HIV-1 compared to these other ligands, with peak production 364 not occurring until 24-48 hours after activation compared to just 4 hours with other viruses (19). 365
Thus, induction of the refractory state after exposure to HIV-1 is also likely delayed until after 366 peak IFNα production. The refractory state of pDCs in the blood prior to detectable viremia 367 would then imply that these pDCs had already reached peak IFNα production in vivo. We found 368 that there were increases in plasma IFNα2 levels in some participants at peak pDC frequency, an 369 observation that may have been restricted by the limitations of weekly sampling to identify what 370 would be expected to be a very low, transient increase of IFNα produced prior to viremia (29). 371
However, the added observation that plasma IFNα2 levels negatively correlated with the ability 372 of pDCs to phosphorylate IRF7, is consistent with a refractory state of the pDCs at this stage 373 (Step 5). 374
375
The observations made here were limited by the inclusion of participants enrolled in ATI studies 376 performed in Thailand alone. While it may be presumed that a similar increase in pDC frequency 377 and decrease in function would be seen after ATI in other cohorts, further studies are needed to 378 rule out any effects of genetic background or HIV-1 clade on these observations. We did include 379 participants from RV397 who received VRC01 treatment during ATI in this study after showing 380 that there was no difference in changes of pDC frequency or phenotype compared to placebo 381 treated participants, but it is possible that VRC01 had an indirect effect on pDCs that we did not 382 identify in our analysis. It has been shown that VRC01 did not alter IFNα production by pDCs 383 exposed to HIV-1 in vitro, suggesting that VRC01 does not affect pDC sensing of HIV-1 (61, 384 62). However, pDCs can produce IFNa after sensing immune complexes (63), and, although we 385 did not see differences in pDC increase and activation between placebo and VRCO1 treated 386 participants, we cannot rule out the potential that VRC01 formed immune complexes in vivo 387 which could have enhanced viral sensing by pDCs in VRC01 treated participants. Though we 388 combined participants from multiple ATI studies for this analysis, the number of participants 389 who received no therapeutic intervention was limited and analysis of pDC function and viral 390 sensing in future ATI studies would help further these observations. Sampling frequency was 391 also a limitation of the ATI studies, particularly for the participants who had detectable viral load 392 within two weeks of ATI and thus only had one aviremic time point. Unfortunately, the current 393 sampling regimen is already burdensome for participants and nonhuman primate studies may be 394 necessary for more frequent sampling to better characterize the innate response after ATI. The 395 unavailability of tissue samples in this analysis prevented us from confirming that low level viral 396 replication in tissues is indeed the source of pDC activation. However, the identification of 397 changes in blood pDCs as a potential indicator of HIV replication provides critical information to 398 time the sampling of future studies in order to confirm when viral replication initiates in the 399 tissue, investigate where early replication begins, and study the earliest immune responses to 400 viral replication after ATI. 401 402 It has been estimated that viral replication is initiated once every 5-8 days after ATI based on the 403 time to detectable plasma viremia of greater than 20 copies/mL (64). However, that calculation 404 does not take into account the potential of local control of replicating virus by the immune 405 system. One participant in RV397 did not have plasma viral loads above 20 copies/mL until 42 406 weeks but showed an increased frequency of activated pDCs in the blood early after ATI just 407 prior to a low-level peripheral blood viral load blip of 1.5 copies/mL. These data support our 408 conjecture that pDC dynamics in the blood are an indicator of viral replication in the tissue and 409 may be used to develop a more sensitive estimate of viral reactivation after ATI. Due to the 410 longer time intervals between sampling points during prolonged ATI, we were unable to 411 determine whether multiple reactivation events occurred in the participants with the longest 412 times of aviremia. It has previously been reported that the frequencies of CD30 + T cells 413 increased months prior to viral detection in two participants who had extended aviremia (65). 414
Unfortunately, the levels of HLA-DR and CD38, which we used to measure T cell activation in 415 the three ATI studies, did not change on the T cells prior to viral rebound so we were not able to 416 identify correlations between pDC activation and T cell activation in our analysis. Experiments 417 in nonhuman primates may lead to further understanding of the timing and mechanisms of these 418 early innate immune responses to viral replication, and to identify aspects of the immune 419 response that contribute to control of replication in those with extended aviremia. 420 421 While our data suggest that pDCs are sensing low level HIV-1 replication after ATI, other 422 factors that could be causing pDC activation should also be considered. ART could have an off-423 target effect on pDCs, resulting in pDC activation after antiretroviral (ARV) clearance. However, 424
given that pDC frequency and function recover after ART initiation, this seems unlikely (13, 14) . 425
Further, participants who were on the same ART regimen at the time of ATI had varied times to 426 pDC activation, from 1-3 weeks after ATI, suggesting that ARV clearance was not responsible 427 for pDC activation. It is also conceivable that ARVs were having an indirect effect on the control 428 of other viruses which were then reactivated after ARV clearance and caused pDC activation. 429
However, a virome analysis to identify other viruses activated after ATI was outside the scope of 430 this work. Finally, pDC activation could be a result of microbial translocation in the gut. As early 431 as two weeks after SIV infection, damage to the intestinal epithelium results in microbial 432 translocation that is associated with immune activation, including increased plasma IFNα levels 433 and T cell activation (66, 67). While low levels of IFNα were detected prior to viral detection in 434 participants of the ATI cohorts, there was no evidence of T cell activation before viral detection 435 (40). This does not exclude the potential for microbial translocation, but gut biopsies were not 436 available before viral detection to investigate whether pDCs were being activated and mobilized 437 do to microbial translocation. 438 439 Our data show that activated pDCs were mobilized to the blood prior to detectable viremia after 440 ATI, and that they entered a refractory state after in vivo production of IFNα. Whereas the early 441 activation of pDCs in response to viral infections is well documented, less information is 442 available on the mechanisms that blunt the pDC response to prevent excessive IFNα production. 443
Decreased levels of pIRF7 after in vitro stimulation were associated with higher levels of plasma 444
IFNα2, suggesting that the refractory state of the pDCs is a result of in vivo activation. 445
Decreased expression of type I IFN genes prior to viral detection was associated with a longer 446 time to reach a viral load over 20 copies/mL, indicating that the refractory state of the pDCs may 447 be indicative of a favorable immune response during ATI. Indeed, IRF7 levels decreased in 448 pDCs over time after in vitro stimulated with the TLR7 agonist R848 (44). If the extent to which 449 type I IFN gene expression is lost is a measure of the extent to which pDCs were activated in 450 vivo, these data suggest that a robust and thorough activation of pDCs is associated with longer 451 time to detection of viremia after ATI. 452
453
While the contribution of this pDC activation towards controlling viral replication is yet to be 454 determined, it is known that the timing of IFNα production is important for viral clearance 455 infected mice resulted in prolonged IFNα production by pDCs which was associated with 467 maintenance of CD8 T cell function and eventual LCMV CL-13 clearance (60). These studies 468
show that early and sustained IFNα production is important for an effective immune response 469 and viral clearance. Thus, while the early induction of IFNα production after ATI may have the 470 potential to be beneficial, a blunting of the pDC response may hinder the mobilization of a 471 successful immune response to clear the virus. Therefore, new strategies to boost and sustain the 472 initial interferon-mediated response to replicating virus are needed to potentially sustain HIV-1 473 remission after treatment interruption. 474 475 476
Methods 477 ATI study design. Twenty-nine individuals with HIV-1 who initiated ART during acute 478 infection as part of the RV254 cohort in Thailand (clinicaltrials.gov NCT00796146) and 479 underwent ATI were included in this study (Table 1) . Participants in the RV254 cohort initiated 480 ART during the earliest stages of AHI, as staged according to a previously described sequential 481 algorithm of pooled nucleic acid testing and immunoassays (73). Early initiation of treatment is 482 associated with preserved immune function and decreased viral reservoir seeding, making 483 individuals in the RV254 cohort ideal for enrollment in ATI studies to identify post-treatment 484 controllers (74, 75). As such, participants included in this study were enrolled in one of three 485 ATI studies: RV411, RV409, or RV397 (Supplemental Figure 1) . 486 487 Eight participants who initiated ART during Fiebig stage I of AHI were enrolled in the RV411 488 study (clinicaltrials.gov NCT02614950)(40). Participants in the RV411 study underwent ATI 489 without additional interventions. Plasma viral load was monitored weekly, except weeks 2-6 490 after ATI when twice weekly monitoring occurred. PBMC samples for RV411 participants were 491 limited to the following timepoints: baseline, last aviremic (VL<20 copies/mL), rebound, and 2 492 weeks after ART-reinitiation. The RV409 study (clinicaltrials.gov NCT02475915) included 15 493 participants who initiated ART during Fiebig stages III-IV of AHI, 14 of whom interrupted ART 494 (Kroon, unpublished observations). During the 10 weeks prior to ATI, participants were treated 495 with ART alone (n=5) or with vorinostat, hydroxychloroquine, and maraviroc (VHM) to induce 496 production of latent virus while maintaining ART (n=10). Plasma viral load was monitored 497 weekly for the first 12 weeks after ATI, and biweekly thereafter. PBMC samples were collected 498 at baseline ATI, weekly through week 4, and biweekly thereafter. During the ten weeks pre-ATI, 499
PBMCs were collected biweekly. The RV397 study (clinicaltrials.gov NCT02664415) included 500 18 participants who initiated ART during Fiebig stages I-III of AHI (41). Participants received 501 intravenous injections of the broadly neutralizing antibody VRC01 (n=13) or placebo (n=5) 502 every three weeks during ATI, starting on the day ART was ceased and continuing for 24 weeks 503 or until ART resumption. Plasma viral load was monitored weekly, with twice weekly testing 504 occurring during weeks 2-6 and 26-30. PBMC samples were collected from RV397 participants 505 at baseline, weekly through week 3, and once every 3 weeks after that. All participants in these 506 three studies experienced viral rebound, and ART was resumed after two consecutive viral loads 507 >1,000 copies/mL. At the time of enrollment in the ATI studies, all participants had a CD4 count 508 > 400 cells/µL and had maintained viral suppression (HIV-1 RNA <50 copies/mL) for at least 48 509 weeks. 510 511 RV409 participants receiving VHM and ART were not included in the current analysis due to 512 detection of intervention induced pDC activation prior to ATI. Further, two participants in 513 RV411 and one participant in the ART only arm of RV409 were not included in any analysis due 514 to an extended amount of time between the last aviremic sample collected and the detection of 515 viral RNA in the blood (>2 weeks). 516 517
Measurement of HIV-1 RNA. Plasma viral load was measured quantitatively with the COBAS 518
TaqMan HIV-1 Test (Roche Diagnostics, Branchburg, NJ) with a lower limit of detection of 20 519 copies/mL. Single copy HIV-1 RNA levels were measured retrospectively in samples from 520 RV397 using ultrasensitive hybrid real time/digital PCR with a limit of detection of 0.45 521 copies/mL, as previously described (76, 77) . were stained with Live/Dead for 10 minutes at room temperature before staining for surface 549 markers at 4°C for 20 minutes. Cells were washed twice with PBS containing 2% fetal bovine 550 serum (wash buffer) before fixation with PBS containing 2% formaldehyde. For intracellular 551 cytokine staining, cells were permeabilized in BD Perm/Wash Buffer at room temperature for 15 552 minutes after overnight fixation. The cells were stained with anti-IFNα and anti-TNFα mAbs at 553 room temperature for 30 minutes followed by three washes with perm/wash buffer. All cells 554 were resuspended in PBS containing 2% formaldehyde before being analyzed on a LSRII (BD 555 Biosciences). All flow cytometry data was analyzed with FlowJo v10 (FlowJo, LLC, Ashland, 556 OR). For measurement of SYK phosphorylation, PBMCs were stained immediately after 557 thawing. For measurement of phosphorylated IRF7 and NF-κB, PBMCs were stimulated with 558 2.5ug/mL imiquimod as described below. Cells were stained with Live/Dead and surface 559 markers as previously described. Cells were fixed in pre-warmed PBS containing 2% 560 formaldehyde and incubated for 10 minutes at 37°C. Cells were then permeabilized in BD 561 Phosflow Perm Buffer III and incubated for 20 minutes on ice. Cells were washed 3 times in 562 PBS containing 10% fetal bovine serum, either immediately or after overnight incubation at -563 20°C. After incubation in wash buffer for 30 minutes on ice, cells were stained for 20 minutes at 564 room temperature followed by two washes with wash buffer. For intracellular staining of Ki-67, 565 cells were stained for surface markers as described in the methods followed by fixation and 566 permeabilization with the Foxp3/Transcription Factor Staining Buffer Set. The cells were stained 567 with anti-Ki-67 mAbs for 30 minutes at room temperature followed by washes with Foxp3 568 permeabilization buffer and wash buffer, respectively 569 
